Pfizer Inc
NYSE: PFE
$28.86
+$0.02 (+0.1%)
Closing Price on October 23, 2024
PFE Articles
Here are five solid defensive picks for investors in what is a very expensive market, and they are also under-owned by active fund managers. All are rated Buy at Merrill Lynch.
Published:
Last Updated:
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
Published:
Last Updated:
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.
Published:
Last Updated:
Pfizer shares were up slightly on Monday after the firm announced topline results from its most recent late-stage study in young children with mild to moderate atopic dermatitis, also known as eczema.
Published:
Last Updated:
Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did not necessarily live up to expectations, there is a winner in this.
Published:
Last Updated:
The June 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Intel and Cisco above all other Dow stocks.
Published:
Last Updated:
Running a screen on Finviz reveals that about two-thirds of the Dow’s 30 components are up by double-digit percentages in 2019. Although five of the 30 components still are basically down so far in...
Published:
Last Updated:
Merrill Lynch has many stocks to buy and these are some of its top defensive stocks and dividend stocks that may help insulate investors during pullbacks or times of weakness.
Published:
Last Updated:
Array BioPharma shares shot up on Monday after the firm announced that it would be acquired by Pfizer in an all cash transaction. The boards of directors of both companies have approved the merger...
Published:
Last Updated:
Five of the 30 Dow Jones industrials are down so far in 2019, and some more are literally just one bad day away from being down for the year.
Published:
Last Updated:
The May 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Intel and Apple above all other Dow stocks.
Published:
Last Updated:
The May 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
As of the most recently reported period, short sellers favored Pfizer, Intel and Apple above all other Dow stocks.
Published:
Last Updated: